DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
C1-INH is an investigational drug.
There have been 5 clinical trials for C1-INH. The most recent clinical trial was a Phase 1 trial, which was initiated on November 16th 2016.
The most common disease conditions in clinical trials are Reperfusion Injury, Ischemia, and Wounds and Injuries. The leading clinical trial sponsors are CSL Behring, Universitaire Ziekenhuizen Leuven, and T. van der Poll.
There are twelve US patents protecting this investigational drug and seventy international patents.
Recent Clinical Trials for C1-INH
|Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients||CSL Behring||Phase 3|
|C1-inhibitor in Allergic ASThma Patients||Sanquin||Phase 4|
|C1-inhibitor in Allergic ASThma Patients||ZonMw: The Netherlands Organisation for Health Research and Development||Phase 4|
Top disease conditions for C1-INH
Top clinical trial sponsors for C1-INH
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|C1-INH||Start Trial||Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders||SHIRE VIROPHARMA INCORPORATED (Lexington, MA)||Start Trial|
|C1-INH||Start Trial||Protein biomarkers for immune assessment and prediction of transplant rejection||THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)||Start Trial|
|C1-INH||Start Trial||Process for the purification of C1-inhibitor||The United States of America as represented by the Secretary of the (Washington, DC)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|C1-INH||European Patent Office||3129781||2034-04-09||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|